Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587961 · ClinicalTrials.gov registry record · Early Phase 1
Personalized Theratyping Trial
A Early Phase 1 study of Cystic Fibrosis, sponsored by George Solomon.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03587961 is a Early Phase 1 study of Cystic Fibrosis that is actively recruiting participants, run by George Solomon. The registered enrollment target is 20 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03587961, a Early Phase 1 study of Cystic Fibrosis, is actively recruiting participants, sponsored by George Solomon.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
Conditions Studied
Interventions
- DRUG Symdeko
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2027-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03587961
The ClinicalTrials.gov registry entry for NCT03587961 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (89% lower). The listed sponsor is George Solomon, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Symdeko is the first listed.
NCT03587961 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT03587961 about?
NCT03587961 is a clinical study titled "Personalized Theratyping Trial". The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
What is the current status of trial NCT03587961?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-08-01. Estimated completion is 2027-09-01.
What conditions does trial NCT03587961 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT03587961?
The interventions under investigation include: Symdeko (DRUG).
Who is sponsoring clinical trial NCT03587961?
This trial is sponsored by George Solomon, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03587961 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hormonal Responses to a Mixed Meal in People With Cystic Fibrosis
RECRUITING · Early Phase 1
-
Regional Monitoring of CF Lung Disease
RECRUITING · Early Phase 1
-
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
ACTIVE NOT RECRUITING · Early Phase 1
-
19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis
COMPLETED · Early Phase 1
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.